Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Monique EMM Bos"'
Autor:
Nansi Maliko, Nina Bijker, Monique EMM. Bos, Michel WJM. Wouters, Marie-Jeanne TFD. Vrancken Peeters
Publikováno v:
Breast, Vol 66, Iss , Pp 285-292 (2022)
Introduction: Each year, around 600 young (
Externí odkaz:
https://doaj.org/article/46607e2896464e549e524bb74f6be964
Autor:
Cornelia AM Almekinders, Tessa G Steenbruggen, Ingrid A. Mandjes, Marta Lopez-Yurda, Monique EMM Bos, Terry G Wiersma, Gabe S. Sonke
Publikováno v:
Cancer Research. 83:OT2-15
Background Patients with metastatic breast cancer (MBC) are usually treated with palliative systemic therapy until progression or unacceptable toxicity. When progression occurs, clinicians typically switch to the next line of systemic therapy. Howeve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4e49b6156e2f087447c1ddc5f4092a7
https://doi.org/10.1158/1538-7445.sabcs22-ot2-15-01
https://doi.org/10.1158/1538-7445.sabcs22-ot2-15-01
Autor:
Cornelia AM Almekinders, Inge RHM Konings, Vincent van der Noort, Susan M van den Berg, Monique EMM Bos, Vincent O Dezentjé
Publikováno v:
Cancer Research. 83:OT2-01
Goal To investigate the efficacy of alpelisib added to fulvestrant beyond progression in patients with HR+ HER2- advanced breast cancer (ABC). Background The SOLAR-1 study (Andre et al, 2019) has shown that the addition of alpelisib, an alpha-specifi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc6026bd5824f374490f5f0a44522adb
https://doi.org/10.1158/1538-7445.sabcs22-ot2-01-08
https://doi.org/10.1158/1538-7445.sabcs22-ot2-01-08